MedTrace Logo

Market Research - Acceptability Study for a New PKU Protein Substitute

NCT04318509 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2020-03-24

No results posted yet for this study

Summary

The aim of this study is to demonstrate that a new protein substitute is acceptable and well tolerated in children with PKU.

Conditions

  • PKU
  • Phenylketonurias
  • Inborn Errors of Metabolism
  • Metabolic Disease

Interventions

DIETARY_SUPPLEMENT

GMPOWER

(casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years

Sponsors & Collaborators

  • Dr. Schär AG / SPA

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-04
Primary Completion
2019-05-19
Completion
2019-05-19

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04318509 on ClinicalTrials.gov